Evidence map›Paper›PMID 38055860›Full record

ReviewAlternatives to laboratory animals : ATLA2024

Key Challenges for

Ian Crooks, Julie Clements, Rodger Curren, Xiaoqing Guo, Michael Hollings, Mel Lloyd, Daniel Smart, David Thorne, Elisabeth Weber, Martha Moore

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alternatives to laboratory animals : ATLA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. In Vitro Mouse Lymphoma Cell (L5178Y TkMethods in molecular biology (Clifton, N.J.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ian CrooksB.A.T. (Investments) Limited, Southampton, UK.
Julie ClementsLabcorp Early Development Services, Harrogate, UK.
Rodger CurrenInstitute for In Vitro Sciences, Gaithersburg, MD, USA.
Xiaoqing GuoNational Center for Toxicological Research, Jefferson, AR, USA.
Michael HollingsLabcorp Early Development Services, Harrogate, UK.
Mel LloydLabcorp Early Development Services, Harrogate, UK.
Daniel SmartPhilip Morris International R&D, Philip Morris Products S.A., Neuchatel, Switzerland.
David ThorneB.A.T. (Investments) Limited, Southampton, UK.
Elisabeth WeberOekolab Ges. F. Umweltanalytik, A member of the JT International Group of Companies, Vienna, Austria.ORCID 0000-0001-5458-8426
Martha MooreMartha M. Moore LLC, Little Rock, AR, USA.
Institute for In Vitro Sciences · USNational Center for Toxicological Research · USPhilip Morris International (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to develop recommendations for optimal scientific and technical approaches for conducting

Indexed as

Electronic Nicotine Delivery SystemsTobacco ProductsAnimalsIn Vitro TechniquesMiceNicotineResearch DesignNicotineelectronic nicotine delivery systemsgenotoxicityheated tobacco productsmouse lymphoma assaymutagenesistobacco products

Identifiers

PMID38055860
PMCPMC13021077
OpenAlexW4389371008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.